UK investigators have pulled the plug on the drug trials, saying it is 'useless' in hospitalized COVID-19 patients - but the WHO is not giving up on its trial just yet.
Hydroxychloroquine has been shown to be ineffective against COVID-19 in a large randomized trial conducting in the UK, its chief investigators calling on a stop to its use against the novel coronavirus.
The announcement on Friday 5 June by the researchers running the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial came after...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
